References
- Miles Labs Inc. (USA). Rioprostil. Drugs Future 1985; 10: 207–208
- Shriver D A, Rosenthale M E, Kluender H C, Schut R N, McGuire J L, Hong E. Pharmacology of rioprostil, a new gastric cytoprotective/antisecretory agent. Arzneim Forsch/Drug Res 1985; 35(1)839–843
- Katz L, Genna G, et al. Antisecretory and antigastrin effects of rioprostil in gastric fistula dogs. Gastroenterology 1986; 90: 1484
- Katz L B, Shriver D A, Capetola R J, Genna T, Argentieri D C, Rosenthale M E. Rioprostil prevents gastric lesions induced by nonsteroidal antiinflammatory durgs (NSAIDS) in adjuvant arthritic (AA) rats. Fed Proc 1985; 44: 733
- Quadros E, Ramsamooj E, Radjapaksa T, Wilson D E. Cytoprotective effects of a prostaglandin-E1 (PGE1) analogue: relationship to mucus synthesis and release in man and the rat. Gastroenterology 1984; 86(5)1214, (Abstract)
- Shriver D A, Rosenthale M E. The cytoprotective activity of ORF 15927 against strong acid, strong base, hypertonic saline and thermal injury. Ortho Pharmaceutical Corp, Raritan, NJ 08869. Internal report
- Singer M V, Schulte H, Demol P, Eysselein V, Goebell H. Dose reponse effects of rioprostil, a new synthetic methyl prostaglandin E, on gastric acid secretion and release of gastrin in humans. Gastroenterology 1985; 88: 1588, (Abstract)
- Demol P, Wingender W, Weihrauch T R, Graefe K H. Inhibition of gastric secretion in man by rioprostil, a new synthetic methylprostaglandin E. Arz-neim Forsch/Drug Res 1985; 35(1)861–863
- Demol P, Singer M V, Schulte K, Eysselein V E, Goebell H, Weihrauch T R. Inhibition of meal-stimulated gastric acid secretion in man by rioprostil, a new synthetic methyl prostaglandin E1. Kyoto conference on prostaglandins. Nov 26–28, 1984, 011–4 (Abstract)
- Wingender W, Demol P, Weihrauch T R, Küppers J. Inhibition of gastric secretion in man by rioprostil. Naunyn Schmiedebergs Arch Pharmacol 1984; 325((suppl))131, (Abstract)
- Demol P, Wingender W, Weihrauch T R, Graefe K H. Inhibition of gastric secretion in man by rioprostil, a new synthetic methyl prostaglandin E. Gastroenterology 1984; 86: 1061, 5(2)
- Tittobello A, Passaretti S, Nannini D, Guslandi M. Attivita di un derivato prostaglandinico (rioprostil) sulla secrezione acida, alcalina e mucosa dello sto-maco umano. Eur Rev Med & Pharm Sci 1985; VII
- Demol P, Wingender W, Weihrauch T R. Inhibition der Magensekretion durch Rioprostil–ein neues synthetisches Methyl-Prostaglandin E]. Z Gastroenterol 1984; 22: 451
- Rajapaksa T, Adams A, Ramsamooj E, Quadros E, Wilson D E. The effects of an oral prostaglandin E1 (PGE) analogue on gastric acid and mucous secretion in man. Clin Res 1983; 31: 766, (Abstract)
- Schulte K, Singer M V, Eysselein V E, Goebell H, Demol P, Weihrauch T R. Hemmung der mahl-zeitstimulierten Magensäure-Sekretion durch Rioprostil ein neues synthetische Methyl-Prostaglandin E1. Z Gastroenterol 1985; 23: 513
- Schulte K, Singer M V, Eysselein V E, Goebell H, Demol P, Weihrauch T R. Hemmung der mahl-zeitstimulierten Magensaure-Sekretion durch Rioprostil, ein neues synthetisches Methyl-Prostaglandin E1. Klin Wochenschr 1985; 63(Suppl IV)49
- Dammann H G, Rehner M, Walker T A, Müller P, Simon B. Rioprostil 600 μg nocte: ausgeprägte und langanhaltcnde Hemmung der intragastralen Azid-ität. Z Gastroenterol 1985; 23: 418
- Boucekkine T, Meknini B, Bitoun A, Bernier J J. Treatment of duodenal-ulcer-comparison rioprostil versus placebo. Gastroenterology 1985; 88: 1332
- Damman H G, Walter Th A, Jenzerski H, Miiller P, Simon B. Rioprostil 600 meg nocte: hohe Ulcus duodeni-Heilungsraten, niedrige Nebenwirkungs-rate. Z Gastroenterol 1986; 24: 452
- Businger J A, Miglio F, Vismans F J, Geraedts A AM, Stocker H. Rioprostil, a new prostaglandin-E1 analog, in the once-a-day treatment of acute duodenal ulcer (comparison vs. ranitidine). Scand J Gastroenterol 1989; 24(suppl 000)00